Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Zadaxin in the treatment
of HIV-positive patients with immune reconstitution disorders. Researchers previously used
Thymosin α-1 (Tα1) as an immune adjuvant for people infected with HIV-1 and found that Tα1
and Interferon-α (IFN-α) have a synergistic effect in immune enhancement. In addition,
studies have found that the triple combination of Tα1, IFN-α and Zidovudine (AZT) has better
tolerability, safety and efficacy. After treatment, patients have lower HIV RNA and more
stable high CD4+ T cell counts. In addition, extensive studies on the administration of Tα1
in thymectomized mice have demonstrated its ability to promote immune reconstitution. The
researchers hypothesized that Zadaxin has a better therapeutic effect on HIV-positive
patients with immune reconstitution disorders, can increase the CD4+T cell count, reduce the
viral load, and has better safety.